|drug3530||Treatment As Usual Wiki||1.00|
|drug3153||Social ABCs Wiki||1.00|
|drug341||Attention Training Program Wiki||1.00|
|D001321||Autistic Disorder NIH||0.33|
|D000067877||Autism Spectrum Disorder NIH||0.30|
There is one clinical trial.
The current Sars-CoV-2 (COVID-19) pandemic has created major changes in how physicians perform routine healthcare for our patients, including elective and non-elective surgical procedures. Beginning on March 16th, 2020 Northwell Health postponed all elective surgeries. As the incidence of COVID-19 cases begins to decrease and hospital volume improves we need to ensure the safety of our patients planning surgical procedures. However, at this time there is a scarcity of data regarding the COVID-19 test conversion rate in surgical patients. Our goal is to determine the COVID-19 test conversion rate in these patients to better guide strategies for restarting surgical care in a large-scale pandemic. Patients will be routinely tested with serology and PCR for COVID-19 24-48 hours prior to their scheduled surgery. Those who provide informed consent will be re-tested 12-16 days after discharge from the hospital to determine any potential nosocomial infection rate. Patients will also answer a few questions during their retest to allow the study team to gauge exposure risk postoperatively after leaving the hospital.
Description: Patients that have negative pre-operative testing that convert to positive testing 14 days post-dischargeMeasure: COVID-19 Test Conversion Time: 14 days
Description: Days from hospital admission to discharge.Measure: Duration of Hospitalization Time: 14 days
Description: Patients will be asked to describe if they have had any exposure to COVID-19 positive persons after their hospital stay.Measure: Rate of self-reported COVID-19 exposure Time: 14 days
Description: If patients contract COVID-19 during the postoperative period, what complications occur?Measure: Rate of complications from COVID-19 Time: 14 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports